-
2 months ago | 
acsjournals.onlinelibrary.wiley.com | Adrienne G. Waks |Paolo Tarantino |Emily Chen |Rachel A. Freedman
INTRODUCTION Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in 15%–20% of invasive breast cancers and is an unfavorable prognostic factor.1 The administration of HER2-directed therapy has transformed outcomes for patients who have HER2-positive breast cancer.
-
Nov 14, 2024 | 
thejc.com | Rachel A. Freedman
Last week a Jew was executed in Iran after being sentenced to death for fatally wounding a man. The family of Arvin Nathaniel Ghahremani, 20, said he was defending himself against a knife attack, and after wrestling the weapon off his assailant had tried to get the man to hospital. His family also said “key errors in the case were intentionally ignored” at his trial.
-
Nov 13, 2024 | 
pericles.pericles-prod.literatumonline.com | Chenxi Jiang |Rachel A. Freedman |Rinaa S. Punglia |Ahmedin Jemal
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. Supporting Information Filename Description ijc35257-sup-0001-Supinfo.pdfPDF document, 436.1 KB Data S1. REFERENCES 1, , , , . Trends in radiation therapy among cancer survivors in the United States, 2000-2030. Cancer Epidemiol Biomarkers Prev. 2017; 26: 963-970. 2 Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
-
Oct 24, 2024 | 
jamanetwork.com | Christina A. Minami |Tanujit Dey |Yu-Jen Chen |Rachel A. Freedman
Key PointsQuestion To what extent does health service area contribute to variation in deescalated care in older adults with early-stage hormone receptor–positive breast cancer? Findings In this cohort study with 9173 patients, most variation (61.8%) was attributed to random or unexplained factors. Measured factors, such as health service area (35.3%) and patient factors (2.8%), explained a minority of the variation.
-
Oct 1, 2024 | 
acsjournals.onlinelibrary.wiley.com | Angela N. Giaquinto |Hyuna Sung |Lisa Newman |Rachel A. Freedman
INTRODUCTION Despite decades of declining mortality through earlier detection and advancements in treatment, breast cancer remains the second leading cause of cancer death among women overall and the leading cause of cancer death in Black and Hispanic women. Continued progress may be thwarted by rising breast cancer incidence and long-term consequences of the coronavirus disease 2019 (COVID-19) pandemic, such as delayed diagnosis because of interruptions in routine care.
-
May 20, 2024 | 
ascopubs.org | Rachel A. Freedman |Jennifer L. Caswell-Jin |Mark R. Somerfield
1 This is a rapid recommendation update of that guideline that addresses, in turn, the adjuvant use of the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors abemaciclib and ribociclib in patients with stage II and III breast cancer.
-
Mar 29, 2024 | 
lesswrong.com | Rachel A. Freedman |Henry Papadatos
AI safety researchers often rely on LLM “judges” to qualitatively evaluate the output of separate LLMs. We try this for our own interpretability research, but find that our LLM judges are often deeply biased. For example, we use Llama2 to judge whether movie reviews are more “(A) positive” or “(B) negative”, and find that it almost always answers “(B)”, even when we switch the labels or order of these alternatives.
-
Feb 29, 2024 | 
jamanetwork.com | Julieta Leone |Michael Hassett |Rachel A. Freedman |Sara M. Tolaney
Key PointsQuestion
What is the breast cancer–specific mortality (BCSM) risk over 20 years in men with stage I to III hormone receptor–positive breast cancer? Findings
In this cohort study including 2836 men, the cumulative 20-year risk of BCSM was 12.4% for stage I, 26.2% for stage II, and 46.0% for stage III. Smoothed annual hazard estimates for BCSM revealed an increase in late hazard rates with each incremental node category, reaching a bimodal distribution in N3 and stage III.
-
Oct 27, 2023 | 
healio.com | David Statman |Rachel A. Freedman
You've successfully added Hematology Oncology: Breast Cancer to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ethnic and racial disparities are a major challenge throughout the field of oncology, but especially when it comes to treating metastatic breast cancer.
-
Jun 14, 2023 | 
jamanetwork.com | Olga Kantor |Rachel A. Freedman |Erica L. Mayer |Mariana Chavez- MacGregor
Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor–Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial
Key PointsQuestion
Are there differences in locoregional recurrence by race and ethnicity among patients with hormone receptor–positive, node-negative, early-stage breast cancer?
